financetom
Business
financetom
/
Business
/
PUDO Q1 revenue jumps 64% on growth in returns business
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PUDO Q1 revenue jumps 64% on growth in returns business
Jul 10, 2025 1:25 PM

Overview

* PUDO ( PDPTF ) fiscal Q1 revenue grows 64% yr/yr, driven by returns business

* Comprehensive loss for the period decreased by 67.9% yr/yr

* Returns accounted for 60.6% of revenue, up from 52.4% last year

Outlook

* Company sees increasing opportunities in new business and customer expansion

* PUDO ( PDPTF ) aims to expand U.S. network to support returns service

* PUDO ( PDPTF ) continues to expand PUDO Label Return services with more retailers

Result Drivers

* RETURNS BUSINESS - Volume increased by over 500%, driving revenue growth, per CEO Elliott Etheredge

* REVENUE COMPOSITION - Returns accounted for 60.6% of revenue, up from 52.4% last year

* NETWORK EXPANSION - Expansion of PUDO Label Return services and partnerships with SAAS and 3PL providers contributed to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 C$1.40

Revenue mln

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million
BRIEF-Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million
Mar 19, 2025
March 19 (Reuters) - Paratek Pharmaceuticals: * PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN CHRONIC RHINOSINUSITIS (CRS) * PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO $330 MILLION * PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO $14 PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE Source text: Further company coverage: ...
BRIEF-Building-Products Distributor QXO Clinches Deal For Beacon Roofing- WSJ
BRIEF-Building-Products Distributor QXO Clinches Deal For Beacon Roofing- WSJ
Mar 19, 2025
March 19 (Reuters) - * BUILDING-PRODUCTS DISTRIBUTOR QXO CLINCHES DEAL FOR BEACON ROOFING- WSJ * QXO HAS AGREED TO PAY $124.35 A SHARE FOR BEACON ROOFING SUPPLY, VALUING BEACON AT ROUGHLY $7.7 BILLION, OR $11 BILLION INCLUDING DEBT- WSJ Source: https://tinyurl.com/4946kcu2 Further company coverage: ...
Building products distributor QXO clinches Beacon Roofing in $11 billion deal, WSJ reports
Building products distributor QXO clinches Beacon Roofing in $11 billion deal, WSJ reports
Mar 19, 2025
March 19 (Reuters) - Building-products distributor QXO signed a deal for Beacon Roofing Supply ( BECN ), valuing Beacon at roughly $7.7 billion, or $11 billion including debt, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. ...
Building products distributor QXO clinches Beacon Roofing in $11 billion deal, WSJ reports
Building products distributor QXO clinches Beacon Roofing in $11 billion deal, WSJ reports
Mar 19, 2025
(Reuters) - Building-products distributor QXO signed a deal for Beacon Roofing Supply ( BECN ), valuing Beacon at roughly $7.7 billion, or $11 billion including debt, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved